197 related articles for article (PubMed ID: 30426503)
1. Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Westbrook JA; Wood SL; Cairns DA; McMahon K; Gahlaut R; Thygesen H; Shires M; Roberts S; Marshall H; Oliva MR; Dunning MJ; Hanby AM; Selby PJ; Speirs V; Mavria G; Coleman RE; Brown JE
J Pathol; 2019 Mar; 247(3):381-391. PubMed ID: 30426503
[TBL] [Abstract][Full Text] [Related]
2. CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Westbrook JA; Cairns DA; Peng J; Speirs V; Hanby AM; Holen I; Wood SL; Ottewell PD; Marshall H; Banks RE; Selby PJ; Coleman RE; Brown JE
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26757732
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Coleman R; Finkelstein DM; Barrios C; Martin M; Iwata H; Hegg R; Glaspy J; Periañez AM; Tonkin K; Deleu I; Sohn J; Crown J; Delaloge S; Dai T; Zhou Y; Jandial D; Chan A
Lancet Oncol; 2020 Jan; 21(1):60-72. PubMed ID: 31806543
[TBL] [Abstract][Full Text] [Related]
4. Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Brown J; Rathbone E; Hinsley S; Gregory W; Gossiel F; Marshall H; Burkinshaw R; Shulver H; Thandar H; Bertelli G; Maccon K; Bowman A; Hanby A; Bell R; Cameron D; Coleman R
J Natl Cancer Inst; 2018 Aug; 110(8):871-879. PubMed ID: 29425304
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
9. Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness.
Jami MS; Hou J; Liu M; Varney ML; Hassan H; Dong J; Geng L; Wang J; Yu F; Huang X; Peng H; Fu K; Li Y; Singh RK; Ding SJ
BMC Cancer; 2014 Mar; 14():194. PubMed ID: 24628760
[TBL] [Abstract][Full Text] [Related]
10. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.
Bellanger A; Donini CF; Vendrell JA; Lavaud J; Machuca-Gayet I; Ruel M; Vollaire J; Grisard E; Győrffy B; Bièche I; Peyruchaud O; Coll JL; Treilleux I; Maguer-Satta V; Josserand V; Cohen PA
J Pathol; 2017 May; 242(1):73-89. PubMed ID: 28207159
[TBL] [Abstract][Full Text] [Related]
11. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
12. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.
Pavlovic M; Arnal-Estapé A; Rojo F; Bellmunt A; Tarragona M; Guiu M; Planet E; Garcia-Albéniz X; Morales M; Urosevic J; Gawrzak S; Rovira A; Prat A; Nonell L; Lluch A; Jean-Mairet J; Coleman R; Albanell J; Gomis RR
J Natl Cancer Inst; 2015 Dec; 107(12):djv256. PubMed ID: 26376684
[TBL] [Abstract][Full Text] [Related]
13. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
[TBL] [Abstract][Full Text] [Related]
14. VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Pu H; Zhang Q; Zhao C; Shi L; Wang Y; Wang J; Zhang M
Pathol Oncol Res; 2018 Jul; 24(3):557-565. PubMed ID: 28744693
[TBL] [Abstract][Full Text] [Related]
15. Proteomics Identification and Validation of Desmocollin-1 and Catechol-O-Methyltransferase as Proteins Associated with Breast Cancer Cell Migration and Metastasis.
Faktor J; Knopfova L; Lapcik P; Janacova L; Paralova V; Bouchalova P; Muller P; Benes P; Bouchal P
Proteomics; 2019 Nov; 19(21-22):e1900073. PubMed ID: 31617665
[TBL] [Abstract][Full Text] [Related]
16. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
17. Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer.
Bouchal P; Dvořáková M; Roumeliotis T; Bortlíček Z; Ihnatová I; Procházková I; Ho JT; Maryáš J; Imrichová H; Budinská E; Vyzula R; Garbis SD; Vojtěšek B; Nenutil R
Mol Cell Proteomics; 2015 Jul; 14(7):1814-30. PubMed ID: 25903579
[TBL] [Abstract][Full Text] [Related]
18. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Mitri Z; Nanda R; Blackwell K; Costelloe CM; Hood I; Wei C; Brewster AM; Ibrahim NK; Koenig KB; Hortobagyi GN; Van Poznak C; Rimawi MF; Moulder-Thompson S;
Clin Cancer Res; 2016 Dec; 22(23):5706-5712. PubMed ID: 27166393
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
[TBL] [Abstract][Full Text] [Related]
20. Analysis of clinicopathological factors associated with bone metastasis in breast cancer.
Chen J; Zhu S; Xie XZ; Guo SF; Tong LQ; Zhou S; Zhao M; Xianyu ZQ; Zhu XH; Xiong W
J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):122-125. PubMed ID: 23392720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
